Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Leuk Lymphoma. 2021 Aug;62(8):1869-1876. doi: 10.1080/10428194.2021.1894649. Epub 2021 Mar 10.
Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Progression-free survival at 24 months (PFS24) constitutes a survival predictor for some lymphomas but has not been examined in Asian populations. We retrospectively investigated whether PFS24 was predictive of survival outcomes after CHOP treatment in 73 Japanese patients with PTCL. Patients without PFS24 had shorter median subsequent overall survival (OS) (20.2 vs. 121.0 months, < 0.001) and shorter median subsequent progression-free survival (5.0 vs. 17.1 months, = 0.03). Patients without PFS24 had worse overall (62.5% vs. 100%) and complete response rates (45.8% vs. 96.0%) (both < 0.001). PFS24 absence (hazard ratio: 3.34, = 0.004) and poor performance status (hazard ratio: 3.17, = 0.04) were independently predictive of shorter OS. These findings suggest that PFS24 is predictive of survival after CHOP treatment in Japanese patients with PTCL.
外周 T 细胞淋巴瘤 (PTCL) 是一组侵袭性淋巴瘤，通常采用环磷酰胺、多柔比星、长春新碱和泼尼松 (CHOP) 治疗。24 个月无进展生存 (PFS24) 是某些淋巴瘤的生存预测指标，但尚未在亚洲人群中进行过检查。我们回顾性研究了 73 例日本 PTCL 患者 CHOP 治疗后 PFS24 是否可预测生存结局。无 PFS24 的患者后续总生存期 (OS) 更短 (20.2 与 121.0 个月， < 0.001)，无 PFS24 的患者后续无进展生存期 (PFS) 更短 (5.0 与 17.1 个月， = 0.03)。无 PFS24 的患者 OS 总缓解率 (62.5% 与 100%， < 0.001) 和完全缓解率 (45.8% 与 96.0%， < 0.001) 更差。PFS24 缺失 (风险比：3.34， = 0.004) 和较差的体能状态 (风险比：3.17， = 0.04) 是 OS 更短的独立预测因素。这些发现表明，PFS24 可预测日本 PTCL 患者 CHOP 治疗后的生存。
